Wordt geladen...
Improved hemostasis in hemophilia mice by means of an engineered factor Va mutant
BACKGROUND: Factor (F)VIIa-based bypassing not always provides sufficient hemostasis in hemophilia. OBJECTIVES: To investigate the potential of engineered activated factor V (FVa) variants as bypassing agents in hemophilia A. METHODS: Activity of FVa variants was studied in vitro using prothrombinas...
Bewaard in:
| Hoofdauteurs: | , , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2014
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4161283/ https://ncbi.nlm.nih.gov/pubmed/24818532 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jth.12489 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|